Across TCGA pan-cancer cohorts, S100A3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated S100A3 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher S100A3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated S100A3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

GBM, LUAD, and LSCC are the cancer types where S100A3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.239	0.430	.004	8	view →
LUAD	DFS	Median	II,III,IV	0.761	0.945	.010	4	view →
LSCC	DFS	Quartile	All	0.750	0.920	.047	3	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.916	.047	2	view →
CCRCC	OS	Median	II,III,IV	0.639	0.865	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: S100A3 tumor-vs-normal RNA expression · all S100A3 data types